Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to demonstrate the superiority of the mesoglycan (Prisma®),
compared to placebo, in reducing the incidence of thromboembolic complications (relapse /
extension of superficial venous thrombosis (SVT), deep venous thrombosis (DVT), pulmonary
embolism (PE)) in patients who have completed the cycle of therapy of the acute phase after
superficial vein thrombosis.